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Abstract
It has been suggested that pathway analysis can complement single-SNP analysis in exploring genomewide association
data. Pathway analysis incorporates the available biological knowledge of genes and SNPs and is expected to improve the
chances of revealing the underlying genetic architecture of complex traits. Methods for pathway analysis can be classified as
competitive (enrichment) or self-contained (association) according to the hypothesis tested. Although association tests are
statistically more powerful than enrichment tests they can be difficult to calibrate because biases in analysis accumulate
across multiple SNPs or genes. Furthermore, enrichment tests can be more scientifically relevant than association tests, as
they detect pathways with relatively more evidence for association than the remaining genes. Here we show how some well
known association tests can be simply adapted to test for enrichment, and compare their performance to some established
enrichment tests. We propose versions of the Adaptive Rank Truncated Product (ARTP), Tail Strength Measure and Fisher’s
combination of p-values for testing the enrichment null hypothesis. We compare the behaviour of these proposed methods
with the established Hypergeometric Test and Gene-Set Enrichment Analysis (GSEA). The results of the simulation study
show that the modified version of the ARTP method has generally the best performance across the situations considered.
The methods were also applied for finding enriched pathways for body mass index (BMI) and platelet function phenotypes.
The pathway analysis of BMI identified the Vasoactive Intestinal Peptide pathway as significantly associated with BMI. This
pathway has been previously reported as associated with BMI and the risk of obesity. The ARTP method was the method
that identified the largest number of enriched pathways across all tested pathway databases and phenotypes. The
simulation and data application results are in agreement with previous work on association tests and suggests that the
ARTP should be preferred for both enrichment and association testing.
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Introduction
Pathways are groups of biologically related genes that act
together in a specific biological process. Different pathways are
responsible for different outcomes varying in complexity. An
example of a biological pathway is the metabolic Gluconeogen-
esis pathway that is responsible for the generation of glucose.
According to the KEGG database [1] this pathway consists of 65
genes, among them the genes GCK (glycokinase) and GPI
(glucose-6-phosphate isomerase). GCK produces glucose-6-phos-
phate and GPI catalyses the reversible isomerization of glucose-6-
phosphate. Both actions take part in energy pathways like
Gluconeogenesis. Pathways may not work correctly due to a
faulty signal received from one of the participating genes. Faulty
pathways can result in disease; therefore pathway analysis is
potentially important since it can reveal the underlying genetic
structure of a disease. Pathway analysis incorporates the available
biological knowledge of genes and simultaneously tests all
pathway genes for association with a phenotype of interest.
Several authors have discussed how pathway analysis can
complement single-SNP analysis in exploring data from genome-
wide association scans (GWAS) [2,3].
Pathway analysis is currently a popular topic and several
methods have been published both for GWAS and a wider range
of molecular analyses [3–11]. The proposed methods are
distinguished by a number of aspects. Some of the methods
require as their input data the raw genotype data, while other
methods require only summary SNP or gene statistics. The
methods also differ in their test statistics and on the way of
assessing the significance of those statistics.
The methods can also be divided into association and
competitive methods according to the null hypothesis tested
[12]. The self-contained (or association) null hypothesis states that
no pathway genes are associated with the phenotype. Testing the
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self-contained null hypothesis compares the statistics of the genes
within the pathway to the null background. Therefore, association
methods can be used in both pathway analysis and candidate gene
analysis, since only the statistics from a selection of genes is
required [2]. For example, some association tests combine the
pathway gene p-values into a single p-value for the entire pathway,
as done by Fisher’s product method, Truncated Product methods,
and the Tail Strength Measure [11,13,14]. Regression models are
also used to assess the joint significance of all pathway genes [15].
Alternatively, the competitive (or enrichment) null hypothesis is
that the pathway genes are no more associated with the phenotype
than the non-pathway genes. The competitive methods compare
the statistics of the pathway genes with statistics of genes outside
the pathway, to determine whether the pathway is more associated
with the phenotype compared to other pathways. An enriched
pathway can be defined as one whose genes are more strongly
associated with the phenotype than those genes outside the
pathway. Commonly used methods that identify enriched
pathways are the Hypergeometric Test, Gene Set Enrichment
Analysis and the SNP ratio test [3,7,9].
The two null hypotheses are related since by rejecting the
competitive null hypothesis, the self-contained null hypothesis is
also automatically rejected. In other words a pathway that is not
associated cannot be enriched. The two hypotheses are equivalent
only in the case that there are no associated genes outside the
pathway. A method testing the self-contained null hypothesis will
have more power than one testing the competitive null hypothesis,
in that an association method will reject the null hypothesis for
more pathways than a competitive method. The competitive null
hypothesis in contrast makes a stronger statement, in this way
sacrificing some of its power. The relationship and differences
between the two null hypotheses have been discussed in detail by
Goeman and Buhlmann [12].
Fridley et al [11] performed a simulation study examining the
performance of existing and novel association methods for
expression data. The methods considered can be divided into
two categories: the methods that are based on summary gene
statistics and those that perform a joint modeling of all the data for
a given pathway. Among the methods considered, the Fisher
product which combines the gene statistics into a single pathway p-
value was shown to have the greatest power in detecting associated
pathways.
In the context of GWAS, population stratification and/or
cryptic relatedness may introduce some biases across the SNPs of
the GWAS [16,17]. These biases make the calibration of
association methods in GWAS difficult. For example, population
stratification inflates the SNP statistics by an average factor l.
While this is usually ignorably close to 1 for single SNP tests, an
appreciable bias may accumulate across multiple SNPs in a
pathway. Although a Fisher product could be rescaled by an
appropriate power of l, it is unclear in general how other
association tests should be adjusted or calibrated. On the other
hand, competitive methods detect pathway genes with relatively
more evidence for association than the remaining non-pathway
genes. Therefore, testing the competitive null hypothesis is more
pragmatic in GWAS, and can be regarded as providing evidence
for pathways of more biological relevance to the phenotype
studied.
In recent years several methods have been proposed for
pathway analysis that either test the self-contained null hypothesis
or the competitive null hypothesis. A parallel development of the
methods has been observed but there has been little overlap in the
literature. In this paper we examine whether commonly used
association methods can test the competitive null hypothesis by
using an appropriate gene statistic. We propose using the scaled
ranks of the gene p-values as the input data of the association
methods, in order to adapt them to competitive tests. This
approach can be used for any association method. Here we adapt
Fisher’s Method (FM) [11], Tail Strength Measure (TSM) [14]
and Adaptive Rank Truncated Product (ARTP) [6] to test the
competitive null hypothesis. A simulation study was performed to
compare the performance of the adapted association methods with
commonly used competitive methods including the Hypergeo-
metric Test [9] and Gene Set Enrichment Analysis (GSEA) [3].
This is the first time that these competitive tests have been
compared to methods derived from association tests. In particular,
the performance of the ARTP has not been compared to other
pathway analysis methods except FM, and has not yet been widely
applied to real studies. However, the results of our simulation
study show that the adapted version of ARTP method is the most
powerful in detecting enriched pathways.
In addition to the simulation study, the methods were applied to
the data of two GWAS. The first study is a subset of the EPIC-
Norfolk study [18] involving 3552 individuals for whom body mass
index (BMI) was recorded. The second GWAS involves 500
healthy individuals and aims to find the genetic structure of
platelet function which is described by four endpoints (phenotypes)
[19,20]. A detailed description of the two studies is given in the
Methods section. The Reactome, KEGG and Biocarta pathways
were downloaded for the analysis performed. Each pathway
database was tested independently from the other databases for
enrichment with the BMI phenotype of the first study and with the
four phenotypes of the second study. The data application results
concur with the simulation results in that the ARTP method is the
most powerful in detecting enriched pathways. This is in
agreement with the literature on association testing, and suggests
that the ARTP method should be preferred for both association
and enrichment testing.
Methods
Ethics Statement
Platelets GWAS: A cohort of 500 healthy subjects of predom-
inantly Northern European origin was recruited from the National
Health Service Blood and Transplant blood donor clinic in
Cambridge after gaining informed, written consent in accordance
with the Declaration of Helsinki (for details of the cohort see Jones
et al (2007) [19]). The study was approved by the Huntingdon
Research Ethics Committee.
The pathway analysis performed was done anonymously for
both EPIC-Norfolk and Platelets GWAS.
Test Statistics
We propose to use scaled ranks of p-values in association
methods, in order to test the competitive null hypothesis. The
methods described here are Fisher’s method (FM), Hypergeo-
metric Test, Tail Strength Measure (TSM), Gene Set Enrichment
Analysis (GSEA) and Adaptive Rank Truncated Product (ARTP).
This section ends with a description of the simulation study data
and the data of the two GWAS used for testing the performance of
the methods.
The association between a gene and the phenotype is often
represented by the minimum p-value of the SNPs assigned to the
gene, with appropriate adjustment for multiple testing in the gene.
A number of other approaches are possible, but the minimum p-
value has generally good properties and is most often used [21]. In
our simulation we avoid this issue by assuming one SNP per gene,
which will not alter our qualitative conclusions. The p-values of
Comparison of Pathway Analysis Enrichment Methods
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association between the GWAS genes and the phenotype are
denoted by pi,i~1, . . . ,K where K is the total number of genes in
the study. The first step for computing the proposed gene statistic
is to rank the gene p-values from the smallest to the largest. The
statistic of the ith gene is denoted by ri and equals the rank of the
ith gene divided by K. Under the null hypothesis, the gene statistics
ri,i~1, . . . ,K follow a discrete Uniform distribution with support
f1=K,2=K , . . . ,1g.
Fisher’s method. Fisher’s method is a well established
association method that combines the results from multiple
statistical tests. The FM test statistic equals
FM~{2
Xm
i~1
log(ri)~{2 log( P
m
i~1
ri) ð1Þ
where m is the number of genes in the pathway. The FM test
statistic follows a x2 distribution with 2m degrees of freedom when
the gene statistics are independent and follow a continuous
Uniform (0,1) distribution. The significance of the calculated FM
test statistic can be estimated by either referring to the appropriate
x2 distribution or by comparing it to a set of null test statistics
computed with randomized gene labels. The gene labels, which
indicate whether a gene is or is not a member of the tested
pathway, are randomly permuted and the FM test statistic is
calculated based on the permuted gene labels. This procedure is
repeated a large number of times to obtain the null permutation
distribution. We used 1000 replicates. The p-value was then
calculated as
pFMP~
P1000
b~1 I(FMpermuted,b§FMobserved)z1
1001
ð2Þ
We were specifically interested in whether the x2 distribution was
accurate when the gene statistics had a discrete distribution.
Hypergeometric test. We define a set of significant genes as
those genes with p-values less than a threshold pt. The
Hypergeometric Test as a competitive method tests whether the
pathway of interest contains more significant genes compared to
those outside the pathway than expected by chance. Suppose that
the pathway has x significant genes, then the p-value of
enrichment of the pathway P with m genes is given by
pHT~
XKS
j~x
K{m
KS{j
 
m
j
 
K
KS
  ð3Þ
where KS is the length of the significant genes list. The
Hypergeometric Test assumes that the significant gene list is
random and conditions on a fixed pathway. This is a one-sided test
testing whether the pathway is enriched/over-represented within
the list of most significantly associated genes with the phenotype.
The Hypergeometric Test is a commonly used competitive test
that is incorporated in a number of bioinformatics tools as
discussed by Elbers et al [22].
Tail strength measure. The Tail Strength Measure pro-
posed by Taylor and Tibshirani [14] is a measure of the statistical
significance of the global null hypothesis of no gene effects. An
advantage of the TSM is that it is asymptotically normally
distributed. The TSM can be adapted to test the competitive null
hypothesis by using the proposed gene statistic ri. Firstly the m
pathway gene statistics are ranked from the smallest to the largest
such that r(1)ƒr(2)ƒ . . .ƒr(m). The TSM is then calculated as
TSM(r1,r2, . . . ,rm)~
1
m
Xm
i~1
f1{r(i)mz1
i
g ð4Þ
TSM calculates the deviation of each gene statistic from its
expected value and large positive values of the TSM indicate
Table 1. Mean type-I error of the methods.
Method Mean Type-I Error
FMc2 0.050
FMP 0.051
Hypergeometricpt~0:05 0.028
Hypergeometricpt~0:01 0.023
Hypergeometricpt~0:005 0.019
HypergeometricKS~2000 0.038
TSMN 0.028
TSME 0.057
TSMP 0.051
GSEA 0.049
ARTP 0.048
ARTPE 0.046
Mean type-I error of the methods across all null scenarios of the simulation
study. TSMN refers to the approximate Normal distribution of the TSM. FMP and
TSMP refer to the permutation procedures for estimating the significance of the
FM and TSM statistic. ARTPE and TSME are the empirical distributions of ARTP
and TSM respectively.
doi:10.1371/journal.pone.0041018.t001
Table 2. Mean power of the methods for the different
pathway sizes.
Method Pathway Size Mean Power
ARTPE 20 0.743
60 0.892
100 0.925
FMx2 20 0.730
60 0.889
100 0.925
GSEA 20 0.639
60 0.826
100 0.867
TSME 20 0.619
60 0.837
100 0.894
HypergeometricKS~2000 20 0.560
60 0.729
100 0.803
The mean power of the methods is computed for all the scenarios for the three
different tested pathway sizes across all other variables.
doi:10.1371/journal.pone.0041018.t002
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evidence against the global null hypothesis, i.e. evidence that the
pathway contains more significant genes than expected by chance.
One of the advantages of the TSM is that, under the global null
hypothesis, it is normally distributed for large enough m, with
mean zero and variance 1
m
. In practice pathway sizes are not large
enough for validating the normal approximation. We computed
an empirical distribution of TSM for pathways of size m by
randomly selecting m p-values from a Uniform (1=2m,1z1=2m)
distribution, calculating the TSM statistic, and repeating the
procedure 1|105 times. An alternative approach would be to use
a discrete Uniform distribution in simulating the empirical
distribution of the TSM. This would probably be more accurate
than the continuous one but the latter works particularly well as we
show in Results. In addition to the normal and empirical
distributions of the TSM, we also compared the observed measure
with a set of null measures computed with randomized gene labels,
as described above for FM.
Gene set enrichment analysis. Wang et al [3] modified the
widely-used method for microarray data, Gene Set Enrichment
Analysis, to perform a gene-based pathway analysis of GWA data.
GSEA, which is based on a weighted Kolmogorov-Smirnov-like
running sum statistic, tests for over-representation of the pathway
genes within the entire ranked list of genes. We use the negative
logarithm of the gene p-values as the input gene statistics, denoted
by pi. We have chosen this input gene statistic as we found it to
give more numerically stable results than others, especially the
gene p-value itself. The gene statistics are ranked from the largest
to the smallest (with p(i) denoting the i
th largest gene statistic). The
weighted Kolmogorov-Smirnov-like running sum statistic is given
by
ES(P)~ max
1ƒiƒK
(
X
Gl[P,lƒi
Dp(l)D
KR
{
X
Gl=[P,lƒi
1
K{m
) ð5Þ
where m is the size of pathway P and KR~
P
Gl[P
Dp(l)D. The
significance of the statistic can be estimated by comparing it to a
set of null statistics computed with randomized gene labels.
Adaptive rank truncated product. Yu et al [6] proposed
the Adaptive Rank Truncated Product for performing a gene-
based pathway analysis. Again we assume that statistics of the m
pathway genes are ranked such that r(1)ƒr(2)ƒ . . .ƒr(m). The
original RTP statistic given by
Figure 1. Power of the five methods for different pathway sizes. Plots illustrate the power of the methods when the total number of
associated SNPs equals 100, the proportion of associated SNPs within each pathway is 0.4 and the effect sizes are s2p~4 and s
2
np~1.
doi:10.1371/journal.pone.0041018.g001
Table 3. Power of the methods as the proportion of pathway
SNPs with effects changes.
Proportion
(a) ARTPE x2FM GSEA TSME HypergeometricKS~2000
40% 0.940 0.909 0.881 0.691 0.659
60% 0.985 0.979 0.970 0.878 0.852
100% 1 1 0.990 0.996 0.985
Power of the methods for a pathway of size 20. 50 genes in total have effects.
The effect size s2p of the pathway genes is 4 and the effect size s
2
np of the rest of
the genes is 1.
doi:10.1371/journal.pone.0041018.t003
Comparison of Pathway Analysis Enrichment Methods
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WJ~
XJ
i~1
log(r(i))~log( P
J
i~1
r(i)) ð6Þ
combines the J smallest gene statistics of the tested pathway. In the
adaptive RTP the truncation point J is chosen such that the p-
value of WJ is minimised. The tested truncation points for a
pathway of size m are all the integer values between 1 and m. The
RTP statistic simplifies to the FM test statistic when the truncation
point J is fixed to m. Simulated data with randomized gene labels
are created for both calculating the significance of eachWJ as well
as estimating the appropriate truncation point J. The RTP
statistic
WbJ~
XJ
i~1
log(rb(i)), 0ƒbƒB,1ƒJƒm ð7Þ
is calculated for each truncation point J , for both the observed
data-set and each of the B simulated datasets. Then Ge’s
algorithm is used to estimate the p-value
s^bJ~
PB
b~0 I(W
b
J ƒWbJ )
Bz1
0ƒbƒB,1ƒJƒm ð8Þ
for each WJ and for all data. The p-value for the ARTP statistic
MinP0 of the pathway is estimated as
pARTP~
PB
b~0 I(MinP
bƒMinP0)
Bz1
ð9Þ
Figure 2. Power of the five methods for different proportions (a) of associated SNPs within a pathway of size 60. Plots illustrate
the power of the methods when the total number of associated SNPs equals 100 (plot (A)) and 200 (plot(B)), the effect sizes are s2p~4 and s
2
np~1 for
both plots.
doi:10.1371/journal.pone.0041018.g002
Table 4. Power of the methods for the different pathway
sizes.
Pathway
size s2p s
2
np ARTPE FMx2 GSEA TSME HypergeometricKS~2000
20 4 2 0.550 0.520 0.370 0.360 0.317
4 1 0.803 0.760 0.620 0.539 0.464
2 1 0.571 0.511 0.460 0.389 0.326
60 4 2 0.851 0.825 0.730 0.713 0.528
4 1 0.974 0.959 0.880 0.868 0.725
2 1 0.857 0.828 0.690 0.707 0.546
100 4 2 0.928 0.915 0.820 0.837 0.690
4 1 0.994 0.980 0.860 0.925 0.804
2 1 0.925 0.901 0.820 0.826 0.674
doi:10.1371/journal.pone.0041018.t004
Comparison of Pathway Analysis Enrichment Methods
PLOS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41018
where
MinPb~min1ƒJƒms^
b
J ð10Þ
Ge’s algorithm [23] is used as suggested by Yu et al [6] for
reducing the multiple-level permutation procedure into a single-
level permutation procedure.
An alternative version for calculating the pathway p-value
creates the simulated data-set using p-values from a continuous
Uniform (1=2m,1z1=2m) distribution instead of using permuted
gene p-values. The ARTP significance based on this empirical
distribution is denoted by ARTPE.
Simulation Study
A simulation study was performed to examine the performance
of the adapted versions of the association methods FM, TSM and
ARTP and of the competitive methods Hypergeometric Test and
GSEA for testing the competitive null hypothesis. The type-I error
and the power of methods were examined under various scenarios.
To estimate the type-I error of the methods, data were created
under the competitive null hypothesis that the pathway is not
enriched. Then, data were created under the alternative hypoth-
esis of enrichment to estimate the power of the methods. In the
simulation study the effects of the following variables were
examined: pathway size, total number of genes with effects, the
variance of the effects of pathway genes, the variance of the effects
of non-pathway genes and the proportion of pathway genes with
effects.
In the simulation study a genotype matrix X of size N|L with
entries 0, 1 and 2 was created. N denotes the total number of
individuals and L the total number of SNPs in the study. The
minor allele frequency (MAF) of each SNP of the study was
randomly selected from a Uniform (0, 0.5) distribution. The
entries 0, 1 and 2 of each column of the genotype matrix X were
sampled with probabilities equal to the genotype frequencies
calculated from the MAF of each SNP under Hardy-Weinberg
equilibrium.
In the subsequent steps of the simulation study, a single-SNP
analysis is performed to test the association of each SNP with the
response variable/phenotype. Each SNP is mapped to a unique
gene so that the simulation regards SNPs and genes as equivalent.
For testing the type-I error of the methods, a number of SNPs
were randomly selected from the L SNPs of the study. Following a
quantitative genetic model, these SNPs were each assigned a
random effect, denoted by b, drawn from a Normal distribution
with mean zero and variance s2. The variance values 1, 2 and 4
were considered. Other SNPs had no effect. The pathway SNPs
were also randomly selected. Selection of the pathway members
and the SNPs with effects were independent steps that could be
done in any order.
In the non-null scenarios the first step was to select the pathway
SNPs. A proportion (a) of pathway SNPs/genes were selected as
having non-zero effect on the response variable. We assume the
effect of pathway genes is stronger than of non-pathway genes by
drawing pathway effects from N(0,s2p) and non-pathway effects
from N(0,s2np) with s
2
p[½2,4, s2np[½1,2 and s2npvs2p. The greater
variance of the effects within the pathway represents an
enrichment of association compared to genes outside the pathway,
as in these scenarios the effect sizes of the genes within the
pathway are larger than the non-pathway genes.
For both cases, the last step in constructing the data of the study
is to calculate the response variable y for the N individuals. An
additive SNP model is assumed for each individual, such that the
response of individual j is calculated as:
yj~
XL
i~1
XijbizN(0,1) ð11Þ
where effectively only the SNPs with effects play a role in the value
of y.
For all null and non-null scenarios of the simulation study,
pathway sizes of 20, 60 and 100 SNPs were tested, which is typical
of current databases. The total number of SNPs with effects varied
with 50, 100 and 200 SNPs. The total number of individuals
tested was 100 and the total number of SNPs/genes was 20000.
These numbers are smaller than found in a typical GWAS but
were chosen to achieve power levels in the relevant range of
50%{80%, while allowing the simulation to complete in a
reasonable time. One thousand simulated datasets were created
for each scenario tested, giving standard errors for the estimated
power of v1:6%. All tested scenarios can be found in table S1.
Data Application
Further to the simulation study data, the methods were applied
on the data of two GWAS for finding their enriched pathways.
The phenotype of the first study is BMI which was measured for
3552 individuals living in Norfolk,UK. This GWAS is a subset of
the EPIC-Norfolk study [18], which is part of the European
Prospective Investigation into Cancer and Nutrition (EPIC)
(http://epic.iarc.fr/) study and involves over 30,000 individuals
living in Norfolk, UK.
The second GWAS aims to find the genetic architecture of
platelet function. Platelets play a key role in thrombus formation
during normal hemostatic responses to injury and atherothrom-
botic events. Platelet function as discussed by Jones et al [19,20]
can be measured by the four endpoints (phenotypes): p-selectin
and fibrinogen responses to both ADP and collagen agonists.
These four phenotypes were measured for the 500 individuals
previously described by Jones et al [19,20]. The 500 individuals of
the study were genotyped using the Illumina610 chip. Standard
quality control filters were applied to both SNPs and individuals,
with 480 individuals and 544,078 SNPs retained for analysis.
The following steps were taken before applying the methods to
the data of the two studies. The SNPs of each study were mapped
to genes according to physical distance: a SNP was mapped to the
closest gene whose coding sequence began v10kb from the SNP.
The minimum p-value of all the SNPs mapped to a gene was then
assigned to the gene. As discussed by others [3], larger genes are
more likely to be assigned a smaller p-value. To avoid any biases
because of the gene size, the gene p-values were adjusted using
phenotype label permutations, as follows.
Table 5. Mean power of the methods that have a type-I error
5% across all simulated scenarios.
Method Power
ARTPE 0.846
FMx2 0.840
GSEA 0.768
TSME 0.772
HypergeometricKS~2000 0.687
Mean power of the methods across all simulated scenarios.
doi:10.1371/journal.pone.0041018.t005
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The phenotype labels were permuted and single-SNP analysis
was re-performed. The minimum p-value of all the SNPs mapped
to a gene was assigned to the gene. The adjusted minimum p-value
of the gene is then calculated as
p^~
PB
b~0 I(p
(b)ƒp(0))
Bz1
ð12Þ
where p(0) denotes the observed gene p-value and p(b) denotes the
gene p-value at the bth permutation. One thousand permutations
were performed.
Gene sets were downloaded from the Molecular Signatures
Database of Broad Institute (http://www.broadinstitute.org/gsea/
msigdb/index.jsp). The gene-sets of the pathway databases
Reactome [24,25], KEGG [1] and BioCarta (http://www.
biocarta.com/) were tested for enrichment. Each database was
tested independently from the other databases for enrichment with
each one of the five phenotypes of the two GWAS.
Results
Simulation Study
We performed simulations consisting of several null and
alternative scenarios according to the hypothesis under which
the response variable was computed. In the null scenarios the
computed response was calculated using a number of genes with
non-zero effects. The pathway genes were randomly selected from
the full list of genes. The pathway sizes and the number of genes
with non-zero effects as well as the effect size of the genes were
varied. In the alternative scenarios the pathway genes selected
were divided into pathway genes with effects and pathway genes
with no effects. The response was computed including the effects
of the pathway genes and a number of non-pathway genes that
were randomly selected from the remaining list of genes. The
association of the pathway genes with the response was assumed to
be greater than the association of the rest of the genes. Different
proportions of pathway genes with non-zero and zero effects were
examined as well as different sizes of effects.
In the null scenarios the pathway size, the total number of genes
with effects and the variance of the effect size s2 were varied (see
Methods for full details). Table 1 shows the mean type-I error of
the methods among all tested scenarios. The ARTP (using both
permutations and its empirical distribution), GSEA and FM (using
Figure 3. Pairwise scatterplot of power for the five methods across all simulated non-null scenarios.
doi:10.1371/journal.pone.0041018.g003
Table 6. Pathway Analysis of BMI.
Pathway
Name Size ARTPE FMx2 GSEA TSME HypergeometricKS~2000
Biocarta:
VIP Pathway
19 0.028 0.242 0.024 0.523 0.552
Table shows the nominal p-values of all five methods for the Biocarta VIP
pathway. Biocarta VIP pathway has been reported as being significantly
associated with BMI and the risk of obesity.
doi:10.1371/journal.pone.0041018.t006
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both permutation and asymptotic distribution) have an appropri-
ate 5% error. The low type-I error of the TSM shows that the
normal approximation is invalid for the small pathways examined
in the simulation study. On the other hand, the empirical and
permutation distributions of the TSM have a 5% type-I error. The
Hypergeometric Test also has a low type-I error for the three
different p-value thresholds examined, owing to the fact that it
follows a discrete null distribution and an exact 5% rejection rate
may not always exist. An appropriate type-I error of the
Hypergeometric Test was observed when the number of
significant genes was increased to 2000 for all tested scenarios,
which we denote by HypergeometricKS~2000. Based on these
observations we referred only to the asymptotic distribution of the
FM test statistic (FMx2 ) and empirical distributions of TSM
(TSME ) and ARTP (ARTPE ) in the alternative scenarios of the
simulation study.
The power of FMx2 , HypergeometricKS~2000, TSME , GSEA
and ARTPE was examined in non-null scenarios. In the non-null
scenarios, the pathway size, the total number of genes with effects,
the proportion of pathway genes with effects and the size of
pathway and non-pathway effects were varied. Table 2 shows the
mean power of the methods for three different pathway sizes
averaged over the proportion of significant genes in the pathway
and the effect sizes in and out of the pathway. The power of all
methods increases as the pathway size increases, reflecting both
the increased proportion of pathway genes among the fixed total of
associated genes, and the decreased proportion of non-pathway
genes. In addition, figure 1 shows the power of the methods when
the total number of associated SNPs equals 100, the proportion of
associated SNPs within each pathway is 40% and the effect sizes
are s2p~4 and s
2
np~1. ARTP has the greatest power for all
pathway sizes. FM has a lower power than ARTP for smaller
pathways but as the pathway size increases, the power of FM
increases reaching the power of ARTP. GSEA outperforms TSM
for smaller pathways but as the pathway size increases TSM has a
greater power than GSEA. Hypergeometric Test has the lowest
power among all tested pathway sizes.
The power of all the methods increases as the proportion of
pathway genes with effects increases. While keeping the total
number of genes with effects fixed and increasing the proportion of
pathway genes with effects, the number of non-pathway genes with
effects decreases and as a result the power of the methods increases
(Table 3). Table 3 shows how the power of the methods changes as
the proportion (a) of pathway genes with effects increases. The
ARTP has a significantly higher power than the other methods for
small proportions of associated genes within a pathway. FM has a
comparable power with ARTP especially in cases where the
proportion of pathway genes with effects is high as for example in
the case of all the pathway genes having an effect. TSM
outperforms GSEA when all the pathway genes have an effect
on the response while GSEA outperforms TSM when a smaller
proportion of the pathway genes have an effect on the response.
The Hypergeometric Test has the smallest power for all tested
proportions. Figure 2 shows how the power of the methods
changes with a for a pathway of 60 genes while the effect sizes are
s2p~4 and s
2
np~1. The first plot corresponds to a total number of
100 genes with effects (in and out of the pathway) and the second
plot to a total number of 200 genes with effects. As it can be seen,
as a increases the power of the methods increases, and the power
of the five methods is greater in the first plot compared to the
second plot indicating that the methods are more powerful when
the enriched pathways include most of the genes with effects of the
study.
Table 4 shows the dependence of the power on the effect size
variance s2p of the pathway genes and effect size variance s
2
np of the
non-pathway genes. As can be seen from table 4 both the value of
s2p and the ratio between s
2
p and s
2
np have an effect on the power of
the methods. The methods attain the highest power when s2p
equals 4 and s2np equals 1. The ARTP has the highest power
followed by FM and GSEA. Table 4 also shows that the power of
the methods increases as the pathway size increases.
Table 5 shows the mean power of the methods: FM,
HypergeometricKS~2000, TSME , GSEA and ARTPE across all
simulated scenarios that can be found in the Table S1. As can be
seen from table S1, ARTP has the highest power in most of the
cases and it has the highest mean power across all simulated
scenarios (Table 5). FM is the second most powerful method with
some cases having equal or greater power than ARTP. GSEA and
TSM methods follow. The method with the lowest power in all
tested scenarios is the Hypergeometric Test. Figure 3 displays a
pairwise scatterplot of the five methods across all non-null
simulated scenarios. The points of the scatterplots of ARTP and
FM against the rest of the methods are above the diagonal line
indicating that the ARTP and FM have higher power than the rest
of the methods. The points in the scatterplot of GSEA against
TSM (or vice-versa) fall very close to the diagonal indicating that
the power of the two methods is very similar across all non-null
Table 7. Performance of the methods when applied on the data of the GWAS.
Response KEGG Biocarta Reactome
BMI
FM (
23
31
) ARTP =GSEA (
15
25
) TSM (
44
63
)
25 cm[1ex]Fibrinogen response to ADP
TSM (
29
35
) FM=GSEA (
23
30
) FM (
43
66
)
Fibrinogen response to collagen
FM= TSM (
9
20
) ARTP (
16
34
) ARTP (
29
54
)
P-selectin response to collagen
GSEA (
13
22
) ARTP = FM=TSM (
18
30
) ARTP (
27
52
)
P-selectin response to ADP
GSEA (
17
24
) GSEA (
14
29
) ARTP (
24
46
)
Table shows the method that identifies the largest number of pathways with nominal p-value less than 0.05 for each phenotype and database. The numbers in the
brackets represent the number of enriched pathways identified by the equivalent method divided by the total number of enriched pathways identified by all the tested
methods.
doi:10.1371/journal.pone.0041018.t007
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simulated scenarios (figure 3). Similarly, the power of ARTP is
very close to the power of FM but it is slightly higher.
Data Application
In addition to the simulation study the five methods: FM,
HypergeometricKS~2000, TSME , GSEA and ARTPE were applied
to real data for finding enriched pathways for the phenotypes of
two GWAS. The two studies aim to find the genetic structure of
BMI and platelet function, respectively. Platelet function as
discussed by Jones et al [19,20] is described by four phenotypes:
p-selectin and fibrinogen responses to both collagen and ADP
agonists. A gene-based pathway analysis was performed on the five
phenotypes: BMI, p-selectin response to ADP, p-selectin response
to collagen, fibrinogen response to ADP and fibrinogen response
to collagen (see Methods for full details). The pathways of
Reactome, KEGG and Biocarta databases were downloaded.
Each database was tested independently for enrichment with each
one of the five phenotypes. Tables S2 and S3 show the pathways
identified as enriched by the five methods for both BMI and
platelets GWA data. The pathways given in the tables have been
identified by at least one of the methods as enriched (i.e. with a
nominal p-value less than 0.05).
The pathway analysis of the BMI phenotype replicated the
main result of the pathway analysis performed by Liu et al [26], in
which the Vasoactive Intestinal Peptide (VIP) pathway was
identified as significantly associated with BMI and the risk of
obesity. The ARTP and GSEA identified the VIP Biocarta
pathway as being significantly associated with BMI whereas the
other methods did not (table 6 and table S2).
Table 7 shows the method that identified the largest number of
enriched pathways for each database and phenotype. The
fractions in the brackets represent the number of enriched
pathways identified by the corresponding method divided by the
total number of enriched pathways identified by the five methods.
ARTP is the method that appears in most of the table cells. ARTP
is the method that identified the largest number of associated
pathways with a nominal p-value less than 0.05 in most of the
cases. ARTP is followed by FM and GSEA. TSM appears less
often in the table and the Hypergeometric Test does not appear at
all. No pathways with a p-value less than the corresponding
Bonferroni correction p-value have been identified by the methods
ARTP, FM, GSEA and TSM. On average ARTP followed by FM
performed better than the other methods. This conclusion is
derived from looking at the total number of p-values less than 0.05
which suggests that there are enriched pathways amongst them.
ARTP method has the greatest overall power than the other
methods, even if it has not identified any individual pathways
contributing to the gain of this power.
Discussion
We performed a simulation study to compare the performance
of methods that test the competitive null hypothesis. Two
commonly used competitive methods, Hypergeometric Test and
GSEA, and adapted versions of the association methods FM, TSM
and ARTP were examined. This is the first time that these
association methods have been considered for competitive testing,
allowing a wider comparison of competitive methods than has
previously been possible.
We propose using the scaled ranks of the gene p-values as gene
statistics used by association methods for testing the competitive
null hypothesis. This novel feature enables the use of analytic and/
or empirical distributions of the association test statistics, and the
simulation study showed that these distributions have the correct
type-I error rate. The proposed gene statistics follow a discrete
Uniform distribution between 1 over the total number of genes in
the study and 1, and deviation from uniformity implies enrichment
of the pathway. The use of the scaled ranks as the input gene
statistics provides a direct comparison between the pathway and
non-pathway genes. While an indirect comparison could be
performed by simply evaluating the association statistics under
gene-label permutations, our approach allows rapid assessment of
significance using analytic or empirical distributions. The scaled
ranks do not depend on the underlying distribution of the gene p-
values, and hence on any bias contained therein, and do not
depend on how the gene-level association is derived from single-
SNP tests. Extensive literature exists on methods for summarizing
gene-level association. The power of these methods depends on
the LD between the SNPs in the gene as well as on their allele
frequencies and effect sizes [21,27]. We avoided this issue by
assuming one SNP per gene, but our results will hold qualitatively
for any well calibrated gene-level test. In other words, as the
methods tested here use gene statistics as their input statistics, as
long as the gene statistics have been adjusted to take both LD and
gene size into consideration, those factors should not play a role in
the results of the pathway analysis. If there are systematic
differences in LD and/or effect size between pathway and non-
pathway genes, then more powerful methods could be developed
to exploit such differences, and this is a promising direction for
future work.
It was observed that the Hypergeometric Test can have a lower
rejection rate than the nominal significance rate. This conservative
property results from the discrete null distribution of the test, and
is more profound when the sample size is small [28], in our case
with small pathways. The appropriate type-I error of 5% was
found by fixing the number of significant genes to KS~2000 for
all tested null scenarios. Other approaches such as mid p-value
introduced by Lancaster [29] are available to ensure a correct
type-I error of the Hypergeometric Test. Despite this aspect,
which can reduce power, and the need to pre-specify a significance
threshold (or to consider multiple thresholds with an appropriate
penalty), the Hypergeometric Test is very commonly used as an
enrichment test. In our simulation study, the non-null scenarios
tested involve simulated pathways with genes with relatively larger
effects than the ones outside the pathways. Non-null scenarios in
which enriched pathways have an overabundance of significant
genes with the same effects as the non-pathway genes were not
explicitly tested here. However we expect the same general
conclusions to apply since the net result is again an increase in
total variance of effect sizes within the pathway.
The results of the simulation study suggest that the ARTP can
and should be used as a more powerful test of enrichment. Our
simulation results also agree with the findings of Tintle et al [9]
who showed that the Hypergeometric Test is less powerful than
the GSEA. In addition they showed that the GSEA is less powerful
than the SUMSTAT method which is conceptually equivalent to
the FM tested here. Furthermore, our results agree with the
findings of Fridley et al [11] who showed that FM is the most
powerful method compared to TSM and other methods for testing
the association null hypothesis. However neither group of authors
considered the ARTP, which we have shown to be more powerful
than FM when adapted to enrichment testing. This result concurs
with those of Yu et al [6] who compared ARTP to FM but not to
other methods such as TSM and GSEA.
In addition to the simulation study, the methods were applied to
the data of two GWAS. The pathway analysis of BMI replicated
the main result of the pathway analysis performed by Liu et al [26]
that identified the VIP pathway as significantly associated with
Comparison of Pathway Analysis Enrichment Methods
PLOS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41018
BMI. In our data however, the result was only replicated using the
ARTP and GSEA methods. In addition, a gene-based pathway
analysis was performed on the GWAS that aims to find the genetic
structure of platelet function. The results by applying the methods
on the four endpoints (phenotypes) that describe platelet function
concur with the simulation results that ARTP is the more powerful
method. The ARTP was the method that identified the largest
number of enriched pathways for most of the tested phenotypes
and pathway databases.
The adapted version of ARTP was shown to be the most
powerful for detecting enriched pathways. The ARTP is an
extension of the RTP statistic, which considers the J best gene
statistics of every tested pathway. The use of Ge’s algorithm with
ARTP has the advantage that a single level of permutation is
needed for estimating the best J for each pathway and the p-value
of enrichment between the pathway and the phenotype. We were
surprised that the TSM and GSEA did not have comparable
power to the ARTP. Conceptually the tests are similar, looking for
a deviation from uniformity in the p-value distribution, in
scenarios in which the deviation tends to lie in the tail. The
TSM has the advantage of a known asymptotic distribution.
However, despite its theoretical appeal it appears to have inferior
power to alternative methods considered by us and other authors.
The FM statistic equals the RTP statistic when J is the total
number of genes, as discussed by Dudbridge and Koeleman [13].
It has been shown that ARTP has better power than FM in
realistic scenarios of association testing. Combining all the above,
we recommend the ARTP as the most powerful method for testing
both association and enrichment null hypotheses.
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